--- a
+++ b/clusters/3009knumclusters/clust_63.txt
@@ -0,0 +1,784 @@
+Patient is not a candidate for stem cell transplant due to advanced age or co-morbidities; or the enrollee does not have donor available; or the enrollee declines stem cell transplant due to personal belief; or stem cell transplant is not standard of care based on the risk category of disease
+cHL COHORT ONLY: history of allogeneic transplant
+Must not have received any prior stem cell transplant
+Prior autologous or allogeneic HCT
+Stem cell infusions (with or without total body irradiation [TBI]):\r\n* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion, and no evidence of graft-versus-host disease (GVHD)\r\n* Autologous stem cell infusion including boost infusion: >= 42 days
+Stem cell Infusion without TBI: no evidence of active graft vs host disease and at least 84 days must have elapsed after transplant or stem cell infusion
+Patients are not eligible if they have had or are planned for solid organ transplant; patients who have received allogeneic hematopoietic stem cell transplant are eligible if:\r\n* The transplant occurred at least 90 days prior to registration, \r\n* Patient has no prior acute graft versus host disease (GVHD), and \r\n* Within 48 hours of registration, patient demonstrates at least 90% engraftment, defined as: absolute neutrophil count (ANC) >= 500 mcl, measured over 3 consecutive days or 1 day with an ANC >= 1,000 mcl, or platelets >= 50,000 mcl measured, wherein the patient did not receive any platelet transfusions within 7 days prior to laboratory assessment
+STEP II: Patients must not have received any non-protocol therapy outside of the assigned induction therapy including stem cell transplant
+Patients must meet institutional eligibility requirements for stem cell transplant, including cardiac, renal, liver, and pulmonary requirements
+Stem cell transplant or rescue: patient has not had a prior stem cell transplant or rescue
+Patient must be deemed eligible to proceed with high-dose chemotherapy and autologous stem cell transplantation by local transplant center
+Patients must not be candidates for allogeneic hematopoietic stem cell transplant; NOTE: Subjects up to age 70 years who are considered fit for allogeneic hematopoietic stem cell transplant, should be considered for enrollment on E1910, in order to avoid competing with that study; if a patient is considered unfit for intensive chemotherapy at the time of initial diagnosis, but subsequently achieves a complete remission (CR), then it will be left to the treating physician’s discretion to consider hematopoietic stem cell transplant (HSCT)
+Patients who have had a prior allogeneic stem cell transplant are not eligible\r\n* NOTE: if a patient underwent auto SCT, he/she must demonstrate engraftment (per treating investigator’s discretion) and meet all other hematological requirements
+Prior allogeneic transplant
+Patient must not have received any prior marrow-ablative chemotherapy and autologous hematopoietic cell transplant
+ELIGIBILITY CRITERIA - PHASE II (ARM D): Patient may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of enrollment; patient must be off immunosuppression and without active GVHD prior to enrollment if previous HSCT
+Autologous stem cell transplant
+Subjects who are considered eligible to receive an autologous stem cell transplant
+Prior allogeneic stem cell transplant
+Prior allogeneic stem cell transplant or solid organ transplant
+Stem cell transplant (autologous or allogeneic) within 100 days of study treatment start
+Gene therapy using an integrating vector Allogeneic hematopoietic stem cell transplant at any time not permitted
+Prior peripheral stem cell transplant within 12 weeks of randomization
+Ineligible for hematopoietic stem cell transplant.
+Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration.
+Patients who have received prior allogeneic stem cell transplant
+Previous allogeneic transplant
+B-cell lymphoma patients who have received prior allogeneic stem cell transplant
+Hematopoietic stem cell transplant =< 3 months prior to registration
+Allogeneic stem cell transplant within 100 days before first dose of study drug
+Has had a prior stem cell or bone marrow transplant.
+Patients who completed single autologous stem cell transplant after completion of at most 2 induction regimens (excluding dexamethasone alone) and are in at least stable disease compared to pre-induction in the first 100 days after stem cell transplantation
+Autologous stem cell transplant following myeloablative therapy within 3 months prior to the first dose of abemaciclib or prior allogeneic stem cell transplant at any time; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria
+Allogeneic stem cell transplant patients and any patient who has relapsed within 100 days of stem cell infusion following an autologous bone marrow transplant.
+Patients must not have received allogeneic stem cell transplant
+Autologous hematologic stem cell transplant within 3 months of study entry; allogeneic hematologic stem cell transplant within 6 months; grade II, or greater, active graft-versus-host disease
+Stem cell transplant less than 3 months prior to enrolment.
+Autologous or allogenic transplant within the 60 days prior to Cycle 1 Day 1.
+Prior peripheral stem cell transplant within 12 weeks of the first dose of study treatment
+Prior allogeneic transplant
+Prior allogeneic hematopoietic cell transplant
+Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant
+Any prior allogeneic hematopoietic stem cell or solid organ transplant.
+Has received an allogeneic bone marrow or allogeneic stem cell transplant.
+Considered a potential transplant candidate; the attending/treating physician will determine transplant candidacy at the time of consent
+Subjects for whom there is the prospect of stem cell transplantation in the next 6 months in the treatment plan are excluded (including subjects for whom the PdC regimen is being considered as pre-transplant cytoreduction)
+Patients are not eligible if they have had or are planned for solid organ transplant or allogeneic hematopoietic stem cell transplant
+Prior allogeneic or autologous HCT at any time.
+Previous allogeneic stem cell transplant
+Subjects with lymphoma must have progressed, had stable disease (SD), or recurred after initial treatment regimens that include an anthracycline and an anti-CD20 monoclonal antibody; subjects who relapse >= 12 months after therapy should have progressed after autologous transplant or been ineligible for autologous transplant
+No prior hematopoietic transplant
+Prior hematopoietic transplant
+Previously received a solid organ transplant or allogeneic progenitor/stem cell transplant.
+Suitable candidate to receive allogeneic stem cell transplantation; patient is eligible for study if a suitable candidate refuses to undergo an allogeneic stem cell transplant or a suitable donor cannot be found
+Prior allogeneic stem cell or solid organ transplant
+Recipients of prior autologous hematopoietic stem cell transplantation are ineligible if disease recurrence occurred less than 6 months from their autologous stem cell transplant.
+MCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included a multiagent chemotherapy regimen and prior ibrutinib or other BTK inhibitor therapy; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplant
+BCL6+ DLBCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included an anthracycline, if not contraindicated; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplant
+Completed allogeneic stem cell transplant (allo-SCT) or are eligible for and willing to complete allo-SCT
+Participant has had a prior allogeneic transplant.
+Undergone an allogeneic stem cell transplant within the past 1 year
+Prior allogeneic stem cell transplant.
+Intention to proceed to high dose chemotherapy (HDT) and autologous hematopoietic stem cell transplant (HSCT)
+Adult male and female subjects at least 18 years of age who have had allogenic bone marrow transplant (BMT) or hematopoietic stem cell transplantation (HSCT).
+Patients with relapsed or refractory classical HL who have previously received autologous stem cell transplant (ASCT); patients must have received prior ASCT at least 12 weeks (3 months) before the first dose of ibrutinib or patients with relapsed or refractory HL who have failed at least 2 lines of prior therapy and are not eligible for ASCT due to:\r\n* Inability to achieve a complete response (CR) or partial response (PR) prior to transplant\r\n* Age or comorbid conditions\r\n* Inability to collect stem cells
+Prior allogeneic stem cell transplant
+relapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-HSCT)
+Receipt of previous allogeneic stem cell transplant; receipt of previous autologous transplant for AML or non-AML condition is allowed
+Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to cycle 1 day 1
+Patients must have completed an autologous stem cell transplant after their first course of treatment; patients who have relapsed or progressed at any time prior to transplant are not eligible
+Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ? 2 months must have elapsed since transplant.
+Chemo-sensitive disease; patients with relapsed plasma cell leukemia may have received systemic therapy including an autologous transplant but it is not required; patients with relapsed multiple myeloma (MM) must have received prior systemic therapy including an autologous transplant; patient must be in at least a PR at the time of transplant; early relapse (VGPR) from complete response will be allowed
+Previous allogeneic stem cell transplant
+Undergoing stem cell transplant at Center for Cell and Gene Therapy (CAGT)
+Less than 30 days post-allogeneic stem cell transplant
+Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating procedures
+Undergoing stem cell transplant at Center for Cell and Gene Therapy (CAGT)
+Donors for allogeneic (i.e. human leukocyte antigen [HLA] matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating procedures
+Less than 30 days post-allogeneic stem cell transplant
+History of bone marrow transplant and stem cell rescue
+Prior allogeneic stem cell or solid organ transplant
+Prior autologous stem cell transplant ? 3 months prior to starting CC-90002.
+Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ? 6 months prior to starting CC-90002.
+Patients must have received an allogeneic stem cell transplant for a hematologic malignancy
+Patient must be >= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollment
+INCLUSION CRITERIA FOR STRATUM C: Patient must be:\r\n* >= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollment\r\n* >= 5 years since allogeneic bone marrow transplant prior to enrollment with no evidence of active graft versus (vs.) host disease
+Previous bone marrow or stem cell transplant
+Has received an allogeneic stem cell transplant
+Must have undergone an allogeneic SCT (regardless of stem cell source)
+Patients who have undergone autologous stem cell transplant > 6 months prior are eligible
+Prior autologous and/or allogeneic transplant is permitted although transplant must have occurred greater than 90 days prior to registration
+Patients must have histologically confirmed relapsed or refractory non-Hodgkin’s lymphoma or Hodgkin’s lymphoma (World Health Organization [WHO] criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant; patients may have relapsed after prior stem cell transplant
+One or more prior lines of chemoimmunotherapy and/or monotherapy with rituximab or other anti-cluster of differentiation (CD)20 antibody; patients may have had a prior autologous stem cell transplant but not prior allogeneic stem cell transplantation
+Prior autologous or allogeneic stem cell transplant (SCT)
+There is no upper limit for the number of prior therapies; patients may have relapsed after prior autologous or allogeneic stem cell transplant
+Subjects with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed if
+the subject has recovered from transplant-associated toxicities prior to the first dose of GSK525762, and For subjects with a prior history of allogeneic transplant,
+Patients with systemic T cell lymphomas who relapsed after autologous transplant are eligible
+Prior allogeneic hematopoietic cell transplant
+Subjects with a history of autologous or allogenic stem cell transplantation must have adequate peripheral blood counts independent of any growth factor support, and have recovered from any transplant related toxicity(s) and be at least 100 days post-autologous transplant prior to first dose of study drug or at least 6 months post-allogenic transplant prior to first dose of study drug and not have active graft-versus-host disease (GVHD), i.e., requiring treatment.
+Disease must be refractory to conventional induction therapy or relapsed after initial standard therapy for ALL; any number of prior therapies is permitted and including allogeneic and/or autologous stem cell transplant
+Previous allogeneic hematopoietic stem cell transplant
+Prior allogeneic transplant if performed < 6 months prior to first dose of AMV564, if patient has active GVHD, or if patient has not been off immunosuppressive
+Prior allogeneic hematopoietic stem cell transplants
+Previous allogeneic transplant
+Allogeneic hematopoietic stem cell transplant
+Prior allogeneic stem cell or solid organ transplant;
+Patients may not have had a prior autologous or allogeneic transplant
+Inclusion Criteria:\n\n          1. Subjects must be ? 18 years of age at the time of screening.\n\n          2. Subjects must have a confirmed diagnosis of relapsed/refractory MM as per IMWG\n             criteria (Rajkumar et al, 2014) or intolerant to all established regimens with proven\n             clinical benefit, which include agents from the following 3 classes of anti myeloma\n             therapies: PIs, IMIDs, and mAbs and have measurable disease with at least one of the\n             following criteria:\n\n               1. Serum M-protein ? 0.5 g/dL\n\n               2. Urine M-protein ? 200 mg/24 hours\n\n               3. Serum free light chain (FLC) assay: involved FLC level ? 10 mg/dL provided serum\n                  FLC ratio is abnormal.\n\n          3. Subjects must either be ineligible for or post-autologous stem cell transplant.\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\n          5. Adequate organ and marrow functions as determined per protocol-defined criteria.\n\n        Exclusion Criteria\n\n        Any of the following would exclude the subject from participation in the study:\n\n        Target Disease Exceptions:\n\n          1. Subjects who have previously received an autologous stem cell transplant if less than\n             90 days have elapsed from the time of transplant or the subject has not recovered from\n             transplant associated toxicities prior to the first scheduled dose of MEDI2228\n\n          2. Subjects who have previously received an allogeneic stem cell transplant\n\n          3. Central nervous system (CNS) disease (including meningeal involvement) by MRI or\n             cerebrospinal fluid exam\n\n          4. Known history of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein,\n             skin changes (POEMS) syndrome, plasma cell leukemia, Waldenstrom's macroglobulinemia,\n             or amyloidosis\n\n             Medical History and Concurrent Diseases:\n\n          5. Any condition that, in the opinion of the investigator, would interfere with\n             evaluation of the investigational product or interpretation of subject safety or study\n             results
+Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
+Prior peripheral stem cell transplant within 12 weeks of initiation of therapy
+The patient must be approved for transplant by the treating transplant physician. This includes completion of their pre-transplant workup, as directed by standard Dartmouth Hitchcock Medical Center (DHMC) standard operating procedures (SOPs) (DHMC SOP – Pre-transplant Evaluation of Allogeneic Recipient).
+Allogeneic stem cell transplant within the past 1 year
+Prior autologous stem cell transplant within 6 months of screening date
+History of organ or hematopoietic stem cell transplant.
+Patients with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment
+Patients who are not hematopoietic stem cell transplant candidates are excluded for the DLBCL cohort (cohort #1)
+Autologous transplant within 6 weeks of planned CAR-T cell infusion.
+History of allogeneic stem cell transplant.
+Two prior stem cell transplants of any kind.
+One prior autologous stem cell transplant within the preceding 12 months.
+One prior allogeneic stem cell transplant within the preceding 24 months.
+Patients who have received prior allogeneic stem cell transplant will be permitted to enroll on the protocol
+Prior allogeneic transplant for any hematopoietic disorder
+Patients with systemic T cell lymphomas who relapsed after autologous transplant are eligible
+Prior allogeneic stem cell transplant is not permitted
+Prior organ transplant including allogenic hematopoietic stem cell transplant
+Prior allogeneic transplant, within the last 5 years
+Stem cell transplantation: Previously received an allogenic stem cell transplant; and/or received an autologous stem cell transplant less than or equal to (<=) 12 weeks before the first dose of study drug
+History of allogeneic stem cell transplant
+Relapsed or refractory to prior standard therapy and subjects who are not candidates for high-dose therapy or autologous stem cell transplant
+Autologous hematologic stem cell transplant within 6 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
+Relapsed or refractory disease after allogeneic transplant provided subject is at least 100 days from stem cell transplant at the time of enrollment
+Prior allogeneic stem cell transplant or organ graft
+Prior stem cell transplant.
+Prior autologous stem cell transplant within 6 months of study entry
+We will exclude patients who are eligible for an allogeneic bone marrow transplant at the time of study enrollment; if an enrolled patient subsequently becomes eligible for transplant, they will not be prevented from proceeding to the appropriate clinical treatment indicated
+Hematopoietic stem cell transplant comorbidity index (HCT-CI) >= 3^50
+Patient has had a prior autologous or allogeneic HSCT.
+Patients who have failed a prior autologous transplant are eligible; however, at least 90 days must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous BMT
+Bone marrow transplant or stem cell rescue
+Relapse after allogeneic stem cell transplantation prior to post-transplant day 30
+Autologous transplant must have been done 100 days prior to the study enrollment
+Subject has been informed of the risks and benefits of intensive chemotherapy and autologous stem cell transplant for treatment of mantle cell lymphoma and has refused this option; this discussion must be clearly documented in the medical record at the time of enrollment
+Patients whom have undergone previous autologous stem cell transplant, and have recurrent or residual disease are eligible for this trial
+Prior allogeneic stem cell or solid organ transplant
+Relapsed and/or refractory disease as defined by: a. Clonal relapse after at least one previous line of therapy or high-dose chemotherapy and autologous stem cell transplantation OR b. Refractory disease to prior therapy defined as less than a hematologic very good partial response (VGPR). If previous therapy was autologous stem cell transplant (SCT), must be >= 3 months after SCT
+Received autologous stem cell transplant within 12 weeks before the date of randomization, or the participant has previously received allogeneic stem cell transplant (regardless of timing)
+Plans to undergo a stem cell transplant prior to progression of disease on this study (these participants should not be enrolled to reduce disease burden prior to transplant)
+History of stem cell transplant.
+Subjects must be at least 100 days from prior stem cell transplant (autologous or allogeneic) or donor lymphocyte infusion (DLI)
+Prior radiation: Cranial irradiation, total body irradiation (TBI), or ? 50% radiation of pelvis ? 3 months prior to screening. Focal irradiation: ? 3 weeks prior to screening if radiation field involved a nontarget lesion; ? 6 weeks prior to screening if radiation field involved a target lesion. Note: True disease progression following prior irradiation therapy must be confirmed by Investigator prior to screening. • Bone marrow transplant: < 6 months since allogeneic bone marrow transplant prior to screening. < 3 months since autologous bone marrow/stem cell transplant prior to screening. < 3 months since stem cell transplant (SCT) or Rescue without TBI with no evidence of GVHD prior to screening. • Radioisotopes: fluorothymidine (18FLT) ? 72 hours prior to first dose of study drug
+One or two prior lines of therapy (defined as either one non-transplant regimen such as MelDex, Vel-Dex or CyBorD, daratumumab, one autologous stem cell transplant, or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and autologous stem cell transplant [ASCT])
+Prior autologous stem cell transplant within 12 weeks of initiation of therapy
+Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.
+Patients are eligible > 100 days after autologous stem cell infusion following myeloablative therapy; patients receiving an autologous stem cell infusion to support non-myeloablative therapy (including 131iodine [I]-MIBG given as a single agent) are eligible >= 6 weeks following the stem cell infusion provided they meet the hematologic and other organ function criteria for eligibility; patients who have received an allogeneic stem cell transplant are excluded
+Prior allogeneic bone marrow- or stem cell-transplant
+relapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-HSCT)
+Prior allogeneic stem cell transplant
+> 6 months since previous autologous transplant (if applicable)
+Has received prior autologous hematopoietic stem cell transplant within the last 60 days
+Prior allogeneic stem cell or solid organ transplant
+Prior hematopoietic stem cell transplant for AML
+Patients with any hematologic malignancy undergoing either an unmodified allogeneic HCT or a double umbilical cord blood transplant with or without the infusion of T-cell depleted HLA-haploidentical peripheral blood stem cells
+After failure of allogeneic stem cell transplant (ASCT) or after failure of frontline therapy in subjects who declined or are not ASCT candidates
+Prior stem cell transplant
+Patients with ALL, CLL, NHL with relapsed disease following standard therapy or a stem cell transplant.
+Patients must be at least 90 days post-transplant
+Received an allogeneic stem cell transplant in the past 1 year (if over 1 year post allogeneic transplant, must not have active chronic graft versus host disease [cGVHD])
+Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug administration.
+Patients who have received autologous stem cell transplant (ASCT) =< 12 weeks prior to the first dose of study drug
+Prior autologous bone marrow or peripheral blood stem cell transplantation =< 100 days prior to registration or if recovery from the transplant is inadequate
+History of autologous or allogeneic stem cell transplant
+Planned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted
+Be a recipient of hematopoietic stem cell transplant.
+Eligible for high-dose therapy and autologous stem-cell rescue
+Prior allogeneic stem cell transplant or solid organ transplant
+Prior allogenic stem cell or solid organ transplant
+Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
+PHASE I: Histologically confirmed classical or lymphocyte predominant Hodgkin’s disease that is relapsed or refractory after at least one prior chemotherapy; patients who have not had prior high-dose therapy (HDT)/autologous stem cell transplant (ASCT) must be ineligible for transplant
+PHASE I: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior HDT/ASCT must be ineligible for transplant; prior lenalidomide is not permitted if patients have progressed on therapy
+PHASE IB DOSE EXPANSION: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients who have not had prior HDT/ASCT must be ineligible for transplant; prior lenalidomide is not permitted if patients have progressed on therapy
+PHASE II: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior HDT/ASCT must be ineligible for transplant; prior lenalidomide is not permitted if patients have progressed on therapy
+Patients who are hematopoietic stem cell transplant candidates are excluded
+At least one prior therapy; prior autologous stem cell transplant is permitted; patients with aggressive lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permitted
+Prior allogeneic stem cell transplant is not permitted
+Less than 3 months since prior myeloablative transplant (if applicable); less than 6 months since prior autologous transplant (if applicable)
+Both transplant and non-transplant candidates are eligible
+PART I: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior high-dose therapy (HDT)/autologous stem cell transplant (ASCT) must be ineligible for transplant; prior ibrutinib is not permitted if patients have progressed on therapy
+PART IB: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior HDT/ASCT must be ineligible for transplant; prior ibrutinib is not permitted if patients have progressed on therapy
+Prior hematopoietic stem cell transplant for the diagnosis of MDS
+Prior treatments: patients must have had at least one prior therapy\r\n* Patients with previous autologous transplant are permitted\r\n* Patients who are eligible and willing to undergo autologous transplant should not be enrolled on this trial\r\n* Prior allogeneic transplant is NOT permitted\r\n* Prior treatment with Bruton’s tyrosine kinase (BTK) inhibitors is NOT permitted\r\n* Prior treatment with nivolumab is permitted
+The patient must be approved for transplant by the treating transplant physician. This includes completion of their pre-transplant workup, as directed by standard Dartmouth Hitchcock Medical Center (DHMC) standard of procedure (SOP)s (DHMC SOP – Pre-transplant Evaluation of allogeneic recipient)
+Autologous hematologic stem cell transplant within 3 months of study entry
+Allogeneic hematologic stem cell transplant within 12 months of study entry
+Must have received front-line chemotherapy; no upper limit for the number of prior therapies; patients may have relapsed after prior autologous stem cell transplant or allogeneic stem cell transplant
+Prior allogeneic transplant
+Patients with histologically confirmed multiple myeloma that are being considered for high dose chemotherapy and autologous stem cell transplant
+Prior allogeneic stem cell transplant
+Prior allogeneic transplant
+Prior autologous or allogeneic HCT
+Previous allogeneic hematopoietic cell transplant (HCT)
+History of hematopoietic stem cell transplant (HSCT)
+Has previously received an allogeneic hematopoietic cell transplant or chimeric antigen receptor-modified (CAR)-T cells
+Eligible and willing to proceed with an allogeneic stem cell transplant with an acceptable stem cell donor
+PRIOR TO CELL PROCUREMENT: Diagnosis of recurrent HL or NHL in patients who have failed > 2 prior treatment regimens; patients relapsed after autologous or allogeneic stem cell transplant are eligible for this study
+Diagnosis of AML and MDS according to World Health Organization (WHO) classification that underwent first allogeneic hematopoietic cell transplant (HSCT) with either peripheral blood or bone marrow as the source of the hematopoietic stem cells
+Prior allogeneic stem cell transplant
+Any autologous patient who underwent high dose melphalan (>= 140 mg/m^2) therapy/peripheral blood stem cell (PBSC) rescue for any stage of multiple myeloma and did not participate in another clinical transplant trial whose primary endpoint is also evaluating long-term, disease-free survival or survival; consenting for study between 30 days to 120 days after transplant; earliest can start therapy is 30 days post transplant after recovered from acute toxicity of autologous stem cell transplant (ASCT)
+Patients with or without previous myeloablative autologous transplant
+Subjects must be at least 90 days since autologous stem cell transplant, if performed
+Prior allogeneic hematopoietic cell transplant.
+No further chemotherapy or stem cell transplant (SCT) planned at the time of enrollment
+Has received allogeneic hematopoietic stem cell transplant within 3 months of CAR T cell infusion; hematopoietic stem cell transplant (HSCT) > 3 months from CAR T cell infusion eligible
+Patient must be ? 3 months from hematopoietic stem cell transplant, must not have active GVHD, and must be off all immunosuppression
+Prior autologous stem cell transplant (SCT) in the prior 12 months
+Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma
+Must have a confirmed diagnosis of DLBCL and have progressed following ?2 lines of previous therapy, after autologous stem cell transplant, or not a candidate for autologous stem cell transplant
+Considered transplant-eligible, as determined by the opinion of the investigator at the participating institution; the participating institution does not need to be a transplant center but patients can be referred to a transplant center if needed
+Have undergone autologous or allogeneic stem cell transplant <60 days prior to receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host disease (GVHD) or GVHD requiring immunosuppressive therapy or are being considered for stem cell transplant within 6-12 months of enrollment (note: ponatinib is not to be used as a bridge to stem cell transplant in this trial)
+Autologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant
+Patients must be relapsed or are refractory to at least 3 prior lines of therapy, including both a proteasome inhibitor an immunomodulatory drug (IMiD), and for whom a transplant is not recommended (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)
+Prior allogenic transplant
+Autologous stem-cell transplant in the previous six months
+Prior bone marrow or stem cell transplant
+Patients with the diagnosis of severe AA, who are not currently candidates for an allogeneic stem cell transplant, fulfilling the following criteria:
+Patients may not have had a prior autologous or allogeneic transplant
+Willingness to have an allogeneic transplant
+Recovered (i.e., =< grade 1 toxicity) from the reversible effects of autologous stem cell transplant
+ARM 2 SALVAGE COHORT: Patients with AML who have failed up to one prior salvage therapy (i.e. salvage 1 or 2 status) will be eligible for Arm 2 relapse cohort; allogeneic stem cell transplant for patients in remission at the time of stem cell transplant will not be considered a salvage regimen; similarly, hydroxyurea if used alone will not be considered a salvage regimen
+Stem cell transplant (SCT): at least 8 weeks following autologous SCT and 12 weeks for allogeneic SCT
+Patients who have received a prior stem cell transplant
+Patients had prior autologous or allogeneic stem cell transplant; prior stem cell collection is allowed
+At least 6 weeks from myeloablative therapy and autologous stem cell transplant (timed from stem cell infusion); patients who received stem cell infusion following non-myelo-ablative therapy are eligible once they meet all other eligibility requirements; patient must NOT have received a prior allogeneic hematopoietic stem cell transplant
+TREATMENT: Diagnosis of myeloma after receiving at least one treatment regimen; if patient has received an autologous or syngeneic stem cell transplant (SCT) they must be > 90 days post-transplant (Group A) OR\r\nfollowing autologous or syngeneic SCT (as adjuvant therapy) and < 90 days post-transplant (Group B)
+Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood within 24 months.
+PART 1: History of prior allogeneic transplant
+Diagnosis of a hematological malignancy requiring an allogeneic stem cell transplant consistent with the standard of care
+Patient with MDS who relapse after allogeneic stem cell transplant are eligible if they received standard dose decitabine or 5-azacytidine prior to or after stem cell transplant
+Prior myeloablative or non-myeloablative autologous or allogeneic hematopoietic stem cell transplant using the marrow, peripheral blood stem cells or single or double umbilical cord blood
+Recipients of prior autologous or allogeneic transplant are eligible, as long as at least 3 months have passed since the transplant, and the patient fulfills other eligibility criteria
+Patients who have received a prior allogeneic hematopoietic stem cell transplant (HSCT) and who have either rejected their grafts or who have become tolerant of their grafts with no active GVHD requiring immunosuppressive therapy
+Patients are eligible 12 weeks after autologous stem cell transplant
+Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ? 2 months must have elapsed since transplant.
+Prior stem cell or bone marrow transplant
+Patients ineligible to receive full myeloablative conditioning regimen for allogeneic hematopoietic progenitor cell transplant due to age or comorbidities
+Allogeneic or autologous transplant for AML with infusion of stem cells within 90 days of study entry or on active immunosuppressive therapy for (GVHD) within 2 weeks before study entry
+Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood within 18 months
+Prior autologous or allogeneic hematopoietic stem cell
+Prior allogeneic bone marrow/peripheral blood stem cell transplant
+Patients must not have a prior autologous, syngeneic or allogeneic hematopoietic stem cell transplant
+Major anticipated illness or organ failure incompatible with survival from peripheral blood stem cell (PBSC) transplant
+Subjects with CD19+ B cell lymphomas with no available curative treatment options (such as autologous or allogeneic stem cell transplant [SCT]) who have a limited prognosis (several months to < 2 year survival) with currently available therapies
+Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months
+Preceding allogeneic hematopoietic stem cell transplant (HSCT)
+Patients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host disease
+RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplant
+Patients must be medically ineligible for allogeneic stem cell transplant (alloSCTx) or not have a known fully HLA matched sibling for planned sibling transplant
+Must not have undergone a prior allogeneic donor (related, unrelated, or cord) transplant; prior autologous transplant is not exclusionary
+Prior transplant within 100 days
+Prior autologous stem-cell transplant (SCT) in the prior 3 months
+A prior autologous transplant within 3 months of study entry or allogeneic stem cell transplant
+Patients with the diagnosis of aplastic anemia who are either previously treated or untreated are eligible if they are not currently candidates for an allogeneic stem cell transplant
+Patients that are eligible (including having available donor) and willing to receive an allogeneic stem cell transplant within 4 weeks
+Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation
+Patients must have relapsed after high-dose therapy and autologous transplantation or be ineligible for high-dose therapy and autologous transplantation; patients that have failed autologous transplantation are those with persistent disease > 30 days after transplant; those ineligible for autologous transplant include those with chemoresistant disease (i.e., patients who have not achieved a partial response or better with their most recent chemotherapy regimen), are expected to have a poor outcome from autologous transplant (e.g., DLBCL relapsing within one year of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone [R-CHOP]-like chemotherapy, double hit lymphoma, v-myc myelocytomatosis viral oncogene homolog (avian) positive [MYC+] lymphoma, persistent positron emission tomography [PET] positivity after chemotherapy), are unable to collect sufficient or tumor-free autologous stem cells per Seattle Cancer Care Alliance (SCCA) standard practice, are unable to tolerate the high-dose autologous conditioning regimens, or who refuse a high-dose autologous transplant regimen
+Received a hematopoietic stem cell transplant within the previous 2 months
+Prior autologous or allogeneic transplant
+>= 3 months prior to registration for autologous bone marrow/stem cell transplant
+Patient must have not received any prior high dose chemotherapy and autologous stem cell transplant
+INCLUSION CRITERIA FOR STEM CELL TRANSPLANT WITH CONDITIONING (COHORT 1):
+EXCLUSION CRITERIA FOR STEM CELL TRANSPLANT WITH CONDITIONING (COHORT 1):
+Patients should meet one of the following diagnosis:\r\n* Patients with primary progressive disease on induction therapy with new targeted therapies\r\n* Relapsed/refractory disease on new targeted therapies, i.e. thalidomide, lenalidomide, bortezomib, or other new novel agents such as carfilzomib, pomalidomide\r\n* Patients with relapsed multiple myeloma following previous autologous stem cell transplant\r\n* Plasma cell leukemia at diagnosis\r\n* High-risk patients with presence of chromosome 17p deletion (> 60%) in the bone marrow by fluorescence in situ hybridization (FISH); patients are not required to have prior autologous stem cell transplant
+Malignant conditions or other life threatening disorders correctable by transplant for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as:
+Stem cells: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after 131I-8H9 treatment; the minimum dose for hematopoietic stem cells is 2 x 10^6 cluster of differentiation (CD)34+ cells/kg
+Multiple myeloma (MM) stage II or III patients who have progressed after an initial response to chemotherapy or autologous hematopoietic stem cell transplantation (HSCT) or MM patients with refractory disease who may benefit from tandem autologous-nonmyeloablative allogeneic transplant
+Stem cells from an identical donor could be used for autologous hematopoietic cell transplant (HCT)
+Patients who have had a previous autologous or allogeneic stem cell transplant in the previous 12 months
+Immunoablative or myeloablative stem cell transplant (SCT): >= 6 months must have elapsed from prior autologous transplant; subjects must not have graft versus host disease post autologous transplant
+No subjects who have received an allogeneic hematopoietic stem cell transplant are eligible
+Bone marrow comprising of < 10% lymphoma on most recent biopsy/aspiration (within 9 months of Allo transplant; may have been performed prior to autologous transplant)
+Prior hematopoietic cell transplant: must be >= 3 months after previous transplant
+Two prior stem cell transplants of any kind
+One prior autologous stem cell transplant within the preceding 12 months
+One prior allogeneic stem cell transplant within the preceding 24 months
+Second hematopoietic cell transplant: Must be >= 3 months after prior myeloablative transplant
+Large-cell lymphoma and aggressive T-cell lymphoma: With chemotherapy sensitive disease that has failed autologous transplant or patients who are ineligible for an autologous transplant; chemotherapy sensitive disease is defined as >= 50% reduction in the size of the tumor with the chemotherapy regimen immediately preceding transplant
+Allogeneic transplant with a human leukocyte antigen (HLA)-identical sibling will be recommended for patients < 55 years; if the patient refuses allogeneic transplant, they may still be eligible for this protocol
+Stem cell source
+Transplant able to occur between day +30 and day +90 from transplant one
+If =< 18 years old, prior myeloablative transplant within the last 6 months; if > 18 years old prior myeloablative allotransplant or autologous transplant
+Patients must be ineligible for autologous transplantation due to prior autologous transplant, an inadequate autologous stem cell harvest, inability to withstand a myeloablative preparative regimen, or clinically aggressive/high risk disease
+Stem cells: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment; the minimum dose for peripheral blood stem cells is 2 x 10^6 CD34+ cells/kg
+Autologous stem cell infusion including boost infusion: ?42 days
+Received an allogeneic hematopoietic transplant within 3 months of screening
+If =< 18 years old, prior myeloablative transplant within the last 6 months; if >18 years old prior myeloablative allotransplant or autologous transplant
+Patients with prior stem cell transplants.
+Patients must have received at least 3 prior lines of therapy (Note: Induction therapy and stem cell transplant ± maintenance will be considered as one line).
+Has allogenic haemopoietic stem cell (HSC) transplant.
+Must be transplant ineligible as determined by their physician, or if transplant eligible, not expect to undergo transplant for at least 24 months after study enrollment. • Stem cell harvest and mobilization regimen is acceptable if clinically indicated, but must first be confirmed by the Takeda Medical Monitor.
+History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of Screening
+Prior bone marrow or stem cell transplant.
+Patients who received an autologous stem cell transplant must be ? 3 months post-transplant and all associated toxicities must have resolved to ? CTCAE Grade 1.
+Patients who have had a prior autologous transplant are eligible
+Prior allogeneic stem cell transplant.
+Patients who have received autologous stem cell transplant (ASCT) ? 8 weeks prior to the first dose of study drug or no adequate count recovery
+Subjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic stem cell transplant (based on age, performance status and/or comorbidities) while also having adequate organ function for CAR T cell treatment.
+Prior hematopoietic stem cell transplant
+Have undergone stem cell transplant (SCT), or are considered transplant ineligible.
+Previously received allogeneic stem cell transplant and one or more of the following:
+Adequate organ function for high dose chemotherapy and autologous stem cell transplant (as per institution standard operating procedure [SOP])
+Patients who have received prior allogeneic stem cell transplant
+Meets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those procedures
+Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing < 10/10 HLA allele matched allogeneic transplant are not eligible
+Patients are eligible 12 weeks after myeloablative therapy with autologous stem cell transplant (timed from start of vorinostat); patients must meet adequate bone marrow function definition post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria
+Patients status post-allogeneic stem cell transplant are not eligible
+History of allogeneic organ or stem cell transplant
+Prior allogeneic transplant
+Allogeneic transplant for AML within the previous 6 months (no time limit for autologous transplant)
+Allogeneic organ or stem cell transplant
+Treatment with prior autologous transplant is permitted
+History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of IMP
+The subject must be a recipient of hematopoietic stem cell or solid organ transplant.
+Ineligible for allogeneic stem cell transplant
+Prior allogeneic stem cell transplant or solid organ transplant
+All patients with relapsed/refractory lymphoma must have received or be ineligible for autologous stem cell transplant or be ineligible for allogeneic stem cell transplant\r\n* NOTE: Patients must not have had a prior allogeneic stem cell transplant
+Patients are not eligible who have had a prior allogeneic stem cell transplant\r\n* NOTE: Autologous stem cell transplant is acceptable
+Prior allogeneic stem cell or solid organ transplant
+Prior allogeneic stem cell transplant or solid organ transplant
+Patients who are primarily eligible for autologous stem cell transplant
+All previous chemotherapy or radiation must be completed at least 3 weeks prior to study entry; immunologic therapy must be completed at least 1 week prior to study entry; patients with prior stem cell transplant must be greater than 365 days post-transplant
+Stem cell transplant (SCT): no evidence of active graft vs. host disease for at least 4 weeks; for allogeneic SCT patients, >= 3 months must have elapsed since transplant\r\n* Must have received no more than 1 prior autologous or allogeneic stem cell transplant.\r\n* Patients must be off all systemic immunosuppressive therapy for at least 2 weeks, excluding hydrocortisone for physiologic cortisol replacement
+Is within the first 100 days of having undergone an allogeneic stem cell transplant; otherwise, patients who have received an allogeneic stem cell transplant are allowed as long as they have no evidence of active graft versus host disease (GVHD) or are on immunosuppressive therapy
+Undergone an organ transplant(s) including allogeneic stem cell or bone marrow transplants
+Previous bone marrow or stem cell transplant
+Hematopoietic cell transplant-co-morbidity Index greater than 2
+Patient must be scheduled to receive high dose chemotherapy and autologous stem cell transplant for multiple myeloma
+Patients who have previously undergone autologous stem cell transplant are eligible for this study provided more than 6 months have elapsed from the prior transplant
+Patients must have a minimum stem cell dose of 4x10^6 CD34+ MNC/kg stored for autologous stem cell rescue
+Stem Cell Transplant (SCT): \r\n* Patients are eligible 6 weeks after date of autologous stem cell infusion following myeloablative therapy (timed from first day of protocol therapy)\r\n* Patients are not eligible post allogeneic stem cell transplant\r\n* Patients who have received an autologous stem cell infusion to support non-myeloablative therapy (such as 131 iodine [I]-MIBG) are eligible at any time as long as they meet the other criteria for eligibility
+Disease must be refractory or relapsed after >= 3 prior regimens (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)
+Prior stem cell transplant (autologous or allogeneic)
+Have measurable or evaluable disease, as defined in 2007 Revised Response Criteria for Malignant Lymphoma; HL patients must not be currently eligible for autologous stem cell transplant
+Patients may not have undergone any prior therapy for their AML other than hydroxyurea; however, if patients had an antecedent myelodysplastic syndrome (MDS), prior treatment with a hypomethylating agent or any other therapy (with the exception of allogeneic stem cell transplant) used to treat their MDS is allowed
+Patients with a history of allogeneic stem cell transplant for MDS or any other antecedent hematologic disorder are not eligible
+Has no other hematopoietic stem cell transplant of any type prior to the current planned autologous hematopoietic cell transplant
+Has received any type of hematopoietic cell transplant
+Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior to autologous (auto)-hematopoietic stem cell transplant (HSCT)
+Stem cell infusion without TBI: no evidence of active graft vs. host disease and at least 84 days must have elapsed after transplant or stem cell infusion
+Subjects with multiple myeloma (MM), Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) who are considered eligible for high-dose chemotherapy and autologous PBSC transplant by the transplant team at Kansas University Cancer Center (KUCC); subjects should be enrolled within 30 days of transplant
+Patients with secondary AML, and patients with a prior autologous and allogeneic bone marrow transplant are eligible
+Patients who have received a prior autologous or allogeneic transplant are excluded
+Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months
+Prior allogeneic bone marrow or stem cell transplant
+Prior autologous bone marrow or stem cell transplant within 1 year of enrollment
+Previous allogeneic (allo)-transplant of any kind
+Patients that have received a prior autologous or allogeneic stem cell transplant
+Patients with prior autologous or allogeneic transplant are eligible; patients must be > 100 days post transplant and have no evidence of active GVHD
+Prior autologous or allogeneic stem cell transplant
+Bone marrow/stem cell transplant or infusion without TBI:\r\n* Part A1 or Part C: No evidence of active graft vs host disease and >= 3 months must have elapsed since stem cell transplant or infusion\r\n* Part A2, Part A3, or Part B: No evidence of active graft vs host disease and >= 6 weeks must have elapsed since stem cell transplant or infusion
+Prior allogeneic bone marrow or stem cell transplant
+Prior autologous bone marrow or stem cell transplant or prior radiation therapy (RT) > 20 Gy to a critical organ within 1 year of enrollment
+Prior allogeneic transplant for any hematopoietic disorder
+Subject is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant (HSCT)).
+Autologous bone marrow transplant or stem cell rescue within four months of start of study drug
+Considered eligible for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
+History of autologous or allogeneic stem cell transplant
+Prior allogeneic stem cell or solid organ transplant
+Prior history of hematopoietic stem cell transplant
+Prior allogeneic stem cell transplant
+Prior allogeneic hematopoietic stem cell transplant.
+Unless approved by the medical monitor, may not have received an allogeneic hematopoietic stem cell transplant within 6 months before treatment, or have active graft-versus-host-disease following allogeneic transplant
+Unless approved by the medical monitor, may not have received autologous hematopoietic stem cell transplant within 3 months before treatment
+They have had an allogeneic stem cell transplant (received stem cell from someone else)
+Patients status post allogeneic stem cell transplant.
+Only non transplant candidates or those who opt to forgo autologous stem cell transplant (ASCT) during first line therapy are eligible
+Previous allogeneic stem cell transplant.
+Autologous or allogenic transplant within the 60 days prior to Screening.
+Has received autologous stem cell transplant (auto-SCT) within 12 weeks before the first infusion or is planning for or is eligible for auto-SCT
+Previously treated with brentuximab vedotin, immune-oncology agents, or received an allogeneic or autologous stem cell transplant
+Prior allogeneic stem cell or autologous transplant.
+If a participant has received a transplant as his/her first-line therapy, he/she must be at least 3 months post transplantation and recovered from the side effects of the stem cell transplant.
+Receipt of an allogeneic bone marrow or allogeneic stem cell transplant
+Prior allogeneic or autologous stem cell transplant
+Eligible for allogenic or autologous stem cell transplant
+Prior hematopoietic stem cell transplant.
+Considered eligible for hematopoietic stem cell transplant (allogeneic or autologous) at the time of signing the ICF.
+Has received prior allogeneic transplants or who are planned to undergo umbilical cord blood transplant, receive ex vivo T-cell-depleted hematopoietic stem cells (HSCs), received any in vivo T-cell depleting antibodies, or non-myeloablative conditioning.
+Prior autologous stem cell transplant within 12 weeks
+Autologous stem cell transplant less than 90 days prior to study day 1
+Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Subjects who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of GVHD.)
+Completion of autologous stem cell transplant (SCT) within 100 days prior study start
+Subjects must have histologically documented relapsed or refractory disease, with a diagnosis of one of the following lymphoid malignancies: diffuse large B-cell lymphoma, peripheral T-cell lymphoma (any subtype); subjects must have received at least one prior systemic chemotherapy and must have either received an autologous stem cell transplant, refused or been deemed ineligible for an autologous stem cell transplant
+Allogeneic stem cell transplant within the last 6 months, or active-graft-versus-host disease following allogeneic transplant, or subjects currently on immunosuppressive therapy following allogeneic transplant
+Relapsed or refractory DLBCL, which has been histologically documented, defined as having received at least 2 but no more than 5 prior treatment regimens and ineligible for high-dose chemotherapy supported by autologous stem cell transplant.
+Allogeneic stem cell transplant within the last 6 months, or active graft versus host disease following allogeneic transplant, or autologous stem cell transplant within the last 3 months.
+Autologous or allogenic transplant within the 60 days prior to the Screening visit.
+Subject is likely to be considered for allogeneic transplant in the opinion of the transplant physician (based on age of patient, health, cytogenetics, and/or molecular characteristics)
+Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
+Patients who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than 12 months prior to initiation of study
+Must have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C - enrolment closed)
+Patients may have had a prior autologous stem cell transplant; no prior history of allogeneic stem cell transplant
+Post-autologous stem cell transplant (ASCT) or not a candidate for ASCT; prior allogeneic stem cell transplant is allowed if patient is off all immunosuppressives and has no evidence of active graft-versus-host disease (GVHD)
+Prior peripheral stem cell transplant within 12 weeks of patient registration
+Back-up stem cell source
+Less than 100 days for subjects receiving autologous hematologic stem cell transplant (HSCT); or 6 months for subjects receiving allogenic HSCT or either transplant type, if otherwise not fully recovered from HSCT related toxicity.
+History of hematopoietic stem cell transplant
+have MCL that relapsed after or is refractory to (a) first-line combination chemotherapy with or without stem cell transplant and (b) at least 1 other locally available therapy
+Prior bone marrow or stem cell transplant
+Participant has previously received an allogenic stem cell transplant; or participant has received autologous stem cell transplantation (ASCT) within 12 weeks before Cycle 1 Day 1
+Prior allogeneic hematopoietic stem-cell transplant for participants with DLBCL, FL, MCL, and CLL only. Prior allogenic hematopoietic stem-cell transplant is permitted for participants with ALL
+Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
+Prior allogeneic stem cell transplant
+Patients with diffuse large B cell lymphoma must have received at least two prior therapies and have received, declined or be ineligible for autologous or allogeneic stem cell transplant
+Subjects who have previously received an autologous stem cell transplant are allowed if a minimum of 3 months has elapsed from the time of transplant and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK2879552.
+Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or currently receiving immunosuppressive therapy following allogeneic transplant
+Received autologous hematopoietic stem cell transplant within the last 3 months
+Prior autologous or allogeneic bone marrow or stem cell transplant
+Patients are eligible >= 6 weeks after autologous stem cell transplants or stem cell infusions as long as hematologic and other eligibility criteria have been met
+Patients may have had autologous transplant; they must be at least 100 days post transplant, and have had recovery of their counts with absolute neutrophil count (ANC) > 1000 and platelets greater than 100 K at some point post-transplant, and be without active cytomegalovirus (CMV) or fungal disease
+Participants received an allogeneic stem cell transplant
+Patients must have history of symptomatic myeloma requiring treatment and meet one of the following requirements:\r\n* Have at least 1 high risk feature at diagnosis (including deletion 13 or hypodiploidy by conventional cytogenetics, t(4;14), t(14;16) or deletion 17 by fluorescence in situ hybridization [FISH], beta 2 microglobulin > 3.5, lactate dehydrogenase [LDH] greater than 1.5 x upper limit of normal [ULN], history of plasma cell leukemia) (prior to chemotherapy); OR\r\n* Have progressive disease on primary therapy with or without prior autologous stem cell transplant; OR \r\n* Have persistent or progressive disease following autologous transplant; it is acceptable for these patients to have a second transplant for disease reduction
+Prior allogeneic transplant
+Refractory disease (defined as persistence of evaluable disease after therapy) or relapsed disease following at least one prior treatment regimen that should include autologous stem cell transplant unless a patient was not eligible or refused prior transplant
+Subjects may be enrolled who relapse after autologous stem cell transplant if they are at least 3 months after transplant, and after allogeneic transplant if they are at least 6 months post transplant.
+Prior allogeneic stem cell or solid organ transplant
+Relapsed or refractory DLBCL, defined as having received at least 1 but no more than 3 prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant.
+Allogeneic stem cell transplant within the previous 6 months, or active graft versus host disease following allogeneic transplant.
+Prior autologous hematopoietic stem cell transplant ? 3 months.
+Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ? 6 months.
+Relapsed or refractory disease after allogeneic transplant provided subject is at least 100 days from stem cell transplant at the time of enrollment
+Plans to undergo a stem cell transplant prior to progression of disease on this study (these participants should not be enrolled to reduce disease burden prior to transplant)
+Prior allogeneic stem cell transplant
+Patients who have had allogeneic hematopoietic stem cell transplant (HSCT) are not eligible if they meet any of the following: \r\n* transplant is within 2 months from cycle 1, day 1 (C1D1) \r\n* Has clinically significant graft-versus-host disease requiring treatment\r\n* Has >= grade 3 persistent non-hematological toxicity related to the transplant
+Patients undergoing allogeneic stem cell transplant using a peripheral blood stem cell source
+Patients who have had a prior transplant
+Participant may have failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-SCT)
+Prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy (patients that require immunosuppressive therapy are not eligible within 60 days of therapy)
+Previously received an organ or allogeneic progenitor/stem cell transplant.
+Prior allogeneic stem cell or solid organ transplant
+Note: prior autologous stem cell transplant as well as radiation to the CNS is NOT an exclusion criterion; prior allogenic stem cell transplant IS an exclusion criterion
+Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
+Participant is a candidate for a bone marrow or stem cell transplant within 12 weeks after study enrollment.
+Prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy; (patients that require immunosuppressive therapy are not eligible within 60 days of therapy)
+Autologous hematologic stem cell transplant within 3 months of study entry; allogeneic hematologic stem cell transplant within 12 months; post allogeneic (allo) patients must not have active graft versus-host disease and be off all immune suppression (other than steroids, as above)
+Only patients who received prior systemic therapy with relapsed/refractory organ disease are eligible, unless they have declined or are not eligible for high-dose melphalan and autologous hematopoietic stem cell transplant (HSCT) or any other standard therapy that has been known to be life-prolonging or life-saving
+Relapsed or refractory after an autologous stem cell transplant (ASCT) or at least two prior multi-agent chemotherapy regimens in patients not candidates for ASCT
+Autologous hematologic stem cell transplant within 3 months of study entry. Patients who had prior Allogeneic hematologic stem cell transplant are excluded
+Subject has undergone an allogeneic stem cell transplant within the past year
+The patient must be approved for transplant by the treating Transplant physician; this includes completion of their pre-transplant workup, as directed by standard DHMC SOPs
+Prior allogeneic stem cell or solid organ transplant
+Have received an autologous or allogeneic stem-cell transplant
+Immunomodulatory therapy such as immunomodulatory drugs (Imids) or stem cell transplant within 28 days prior to the first day of treatment
+Has received autologous stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease
+Any antitumor systemic cytotoxic therapies within 28 days prior to enrollment (6 weeks for nitrosoureas or mitomycin-C); prior high-dose chemotherapy with bone marrow or stem cell transplant is excluded
+Prior allogeneic stem cell transplant
+Prior autologous stem cell transplant ?12 weeks prior to first dose of study drug
+Prior allogeneic stem cell transplant (SCT), chest radiation ? 24 weeks from study drug, ?1000 mg of Carmustine Bis-chloroethylnitrosourea (BCNU) as part of pre-transplant conditioning regimen, prior treatment with drug targeting T-cell costimulation or immune checkpoint pathways
+Post autologous stem cell transplant bone marrow biopsy core that is consistent with morphologic remission
+Must have received induction and consolidation chemotherapy, and autologous stem cell transplant for AML
+Patient received another investigational agent after post autologous stem cell transplant
+No autologous or allogeneic stem cell transplant within 3 months prior to cycle 1 day 1
+Patients who have previously undergone allogeneic hematopoietic stem cell transplant will be excluded from this study
+Undergone an allogenic stem cell transplant
+Prior allogeneic transplant (prior autologous stem cell transplant >6 months prior to study entry is permitted)
+Patients must have relapsed or refractory disease following frontline chemotherapy; no upper limit for the number of prior therapies; patients may have relapsed after prior autologous or allogeneic stem cell transplant
+Must not be a candidate for autologous stem cell transplant (ASCT), has declined the option of ASCT, or has relapsed after prior ASCT
+Prior solid organ transplantation or allogenic stem cell transplantation (ASCT). However, previous autologous BM transplant (ABMT) or autologous peripheral blood stem cell transplant (PBSCT) is permitted.
+Prior allogeneic HCT (prior autologous transplant is allowed regardless of response)
+Allogeneic hematopoietic stem cell transplant within 100 days prior to leukapheresis
+Patients who have undergone autologous stem cell transplant more than 3 months prior are eligible
+Stem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: ?84 days after infusion and no evidence of graft versus host disease; Autologous stem cell infusion including boost infusion: ?42 days
+Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with diffuse large B-cell lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplant (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permitted; prior ibrutinib is not permitted
+Prior autologous stem cell transplant =< 12 weeks prior to registration
+Prior allogeneic transplant of any kind
+Inclusion Criteria:\n\n        • Aged 18 years or older, with lymphoid malignancies of B-cell origin as follows:\n\n        *Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma:\n\n        EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma\n\n        INCLUDING: any non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell\n        subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell lymphoma,\n        transformed NHL histologies, etc.\n\n        *Hodgkin's lymphoma\n\n          -  Life expectancy of 12 weeks or longer.\n\n          -  Subject must have received ? 1 prior treatment regimen.\n\n          -  The subject must not be a candidate for potentially curative therapy, including stem\n             cell transplant.\n\n        Exclusion Criteria:\n\n          -  Received an investigational study drug within 28 days or 5 half-lives (whichever is\n             longer) prior to receiving the first dose of study drug.\n\n          -  Received any approved anticancer medications within 21 days or 5 half-lives (whichever\n             is longer) prior to receiving their first dose of study drug (42 days for\n             nitrosoureas) EXCEPT steroids at ? 10 mg prednisone daily (or equivalent).\n\n          -  Has any unresolved toxicity ? Grade 2 from previous anticancer therapy.\n\n          -  Has history of brain metastases or spinal cord compression, or lymphoma involving the\n             central nervous system.\n\n          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of ? 3.\n\n          -  Received allogeneic hematopoietic stem cell transplant within the last 6 months, or\n             has active graft versus host disease (GVHD) following allogeneic transplant, or is\n             currently receiving immunosuppressive therapy following allogeneic transplant.\n\n          -  Received autologous hematopoietic stem cell transplant within the last 3 months.\n\n          -  Laboratory parameters not within the protocol-defined range.\n\n          -  Current or recent history (<30 days prior to screening and/or <45 days prior to\n             dosing) of a clinically meaningful bacterial, fungal, parasitic or mycobacterial\n             infection.\n\n          -  Current clinically active viral infection.\n\n          -  Known history of infection with the human immunodeficiency virus (HIV).\n\n          -  History of active hepatitis or positive serology for hepatitis.
+Prior history of allogeneic hematopoietic stem cell transplant (HSCT).
+Newly diagnosed, symptomatic multiple myeloma patients for whom treatment is indicated per the NCCN guidelines, and for whom a hematopoietic stem cell transplant is not planned or scheduled during the study or are considered ineligible for hematopoietic stem cell transplant, with measurable disease
+Previous participation in a stem cell study within last 30 days
+Participants must not have had a prior transplant
+Prior autologous or allogeneic transplant
+Prior autologous or allogeneic bone marrow/peripheral blood stem cell transplant
+Eligible for allogeneic transplant in the treating physicians’ judgment and by institutional standards
+Subjects with a history of autologous or allogenic stem cell transplant must have adequate bone marrow independent of any growth factor support, and have recovered from any transplant related toxicity(s); and either greater than 100 days post-autologous transplant (prior to first dose of study drug) or greater than or equal to 6 months post-allogenic transplant (prior to first dose of study drug) and not have active graft-versus-host disease (i.e., requiring treatment).
+Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;
+Subject has no available or declines curative treatment options such as allogeneic stem cell transplant (SCT) and has limited prognosis (< 2 years survival) with currently available therapies
+Recovered (i.e., =< grade 1 toxicity) from the reversible effects of autologous stem cell transplant
+Received at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis;
+Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD
+Patient must not have undergone a prior allogeneic stem cell transplant
+Patients who have previously received an autologous stem cell transplantation must be at least 4 weeks post-transplant before study drug administration and must have exhibited a full haematological recovery
+Two prior stem cell transplants of any kind
+One prior autologous stem cell transplant within the preceding 12 months
+One prior allogeneic stem cell transplant within the preceding 24 months
+Myeloablative or non-myeloablative allogeneic hematopoietic cell transplant
+Patients with prior autologous or allogeneic stem cell transplant are eligible as long as they meet all other criteria
+Patients who have received a stem cell transplant in the past.
+Patients who can receive an allogeneic stem cell transplant within 4 weeks.
+Prior allogeneic hematopoietic stem cell transplant
+Prior autologous stem cell transplant within previous 3 months
+Have previously received an allogenic stem cell transplant
+Have received autologous stem cell transplant within 12 weeks before the first infusion
+Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant
+Received a hematopoietic stem cell transplant
+Subject progressed during or within 2 months of completion of their last planned course of salvage therapy with chemotherapy (with or without rituximab, may include autologous stem cell transplant).
+Not a candidate for autologous stem cell transplant (ASCT) or declined option.
+Prior allogeneic stem cell transplant
+The patient had a previous bone marrow or stem cell transplant
+Patients who meet previous criterion or have any of the following are eligible: \r\n* Less than partial response (PR) to salvage chemotherapy\r\n* Kinetic failure\r\n* Having received more than 3 lines of therapy\r\n* Failure to mobilize autologous stem cell\r\n* 10% or more marrow involvement\r\n* 6 months post autologous stem cell transplant
+A prior allogeneic stem cell transplant
+Prior allogeneic hematopoietic stem cell transplant
+Both potentially autologous stem cell transplant (autoSCT) or allogeneic stem cell transplant (alloSCT) candidates and those who are not transplant candidates are eligible for the study
+Autologous stem cell rescue within 12 weeks before study enrollment or those who underwent allogeneic stem cell transplant within one year of enrollment
+Have received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug
+Allogeneic transplant for AML within previous 6 months (no time limit for autologous transplant)
+TRANSPLANT RECIPIENT
+A diagnosis of a hematologic malignancy for which stem cell transplant is standard of care
+If patients are found to not be in remission at screening, then the patient may be returned to their primary hematologist/oncologist or may receive chemotherapy as per standard of care for the malignant disease; patients for whom this would be their first allogeneic transplant must be in remission (< 5% malignant blasts in marrow and peripheral blood and no evidence of extramedullary disease) for transplant; patients enrolled on this protocol for their second transplant do not need to have attained remission prior to transplant
+Patients with prior autologous stem cell transplants will be included; patients with prior allogeneic stem cell transplants will be eligible for 2nd BMT if not previously transplanted with FLT on 11-c-0136
+TRANSPLANT RECIPIENT:
+18F FLT CANDIDATE TRANSPLANT RECIPIENT: Meets criteria for transplant recipients
+CLL subject has undergone an allogeneic or autologous stem cell transplant or NHL subject has undergone an allogeneic stem cell transplant or has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.
+Not eligible for high-dose chemotherapy and stem cell transplant.
+Underwent stem cell transplant <60 days prior to receiving first dose of ponatinib
+Have received at least 2 prior treatment, which may include stem cell transplant.
+Had allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy.
+No autologous stem cell transplant within 6 months prior to registration for protocol therapy
+Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.
+Previously received an allogeneic transplant
+Previous allogeneic stem cell transplant
+Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the past 12 months
+History of allogeneic bone marrow/stem cell transplant
+Prior allogeneic stem cell transplant
+Stem cell transplant within 60 days
+TIER I SUBJECTS: Patients who have had an autologous transplant must wait at least 180 days from day 0 of autologous transplant to be eligible; patients do not have to relapse following transplant to be eligible provided they meet the 180 day wait post day 0 of transplant requirement; transplant date is defined as the day of infusion of stem cells
+Previous allogeneic stem cell transplant
+Patients must have a corrected diffusion capacity >= 50% prior to the autologous transplant and >= 40% prior to the allogeneic transplant
+Receipt of allogenic or autologous stem cell transplant
+Prior autologous hematopoietic stem cell transplant
+Patients who are candidates for allogeneic stem cell transplant at the time of enrollment
+Stem cell transplant within 3 months
+Patients status post-allogeneic stem cell transplant are not eligible.
+Prior hematopoietic stem cell transplant
+Candidates for allogeneic stem cell transplant at the time of screening.
+Not eligible for stem cell/bone marrow transplant or have refused stem cell/bone marrow transplant or have relapsed after autologous or allogeneic stem cell/bone marrow transplant
+Has had a prior stem cell or bone marrow transplant
+Prior allogeneic transplant
+More than 2 months out from allogenic hematopoietic stem cell transplant prior to randomization.
+Must be transplant-eligible per institution guidelines
+Patients after allogeneic stem cell transplantation from a related or unrelated, HLA-matched or mismatched donor with the diagnosis of transplant related microangiopathy. Patients having received any of the following stem cell sources are eligible: G-CSF mobilized peripheral blood stem cells, bone marrow, umbilical cord blood.
+For Pre-allo Part A (before stem cell transplant): Eligible for an allogeneic hematopoietic stem cell transplant
+For Pre-allo Part A (before stem cell transplant): Partially matched donors (related or unrelated) and umbilical cord blood cells are excluded as the source of hematopoietic stem cells
+For Pre-allo Part A (before stem cell transplant): Prior alloSCT
+Transplant within 8 weeks
+Must be relapsed or refractory after autologous stem cell transplant (ASCT) and/or 2 or more prior chemotherapy regimens
+Received autologous stem cell transplant within 28 days or allogeneic transplant within 3 months prior to first dose of study drug
+Prior stem cell transplant
+Stem cell transplant within previous 3 months prior to initiation of study therapy
+Current candidacy for a potentially curative allogeneic stem cell transplant, unless declined
+Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
+Prior autologous or allogeneic hematopoietic stem cell transplant (HSCT)
+Prior allogeneic hematopoietic stem cell transplant.
+Autologous transplant < 12 months prior to enrollment.
+Prior autologous transplant for the disease for which the UCB transplant is being performed.
+Patients who are eligible, willing and able to receive an allogeneic stem cell transplant within 6 weeks are not eligible
+Peripheral autologous stem cell transplant within 12 weeks prior to Baseline; prior allogeneic transplants within 16 weeks or chronic use of immunosuppressants.
+Prior allogeneic hematopoietic stem cell transplant (HSCT)
+Prior allogeneic hematopoietic stem cell transplantation (allogeneic stem cell transplant)
+Prior allogeneic hematopoietic stem cell transplant
+Prior autologous hematopoietic stem cell transplant within 90 days of study entry
+All patients must have received at least one prior regimen for CLL, including cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, a BTK inhibitor, or a PI3K inhibitor. Patients may have received high dose chemotherapy/autologous stem cell transplant (HDT/ASCT) or allogeneic hematopoietic stem cell transplant (allo SCT).
+Prior allogeneic stem cell transplant in previous 3 months
+Patient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT)
+Subjects with prior allogeneic transplant are excluded: however, subjects who have previously received an autologous stem cell transplant are allowed if a minimum of 100 days has elapsed from the time of transplant and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK2816126
+History of (or plans to undergo) spleen removal surgery or allogeneic stem cell transplant
+Patient must be:\r\n* >= 6 months since allogeneic bone marrow transplant prior to registration\r\n* Stem cell transplant or rescue without TBI: no evidence of active graft versus (vs) host disease and >= 3 months must have elapsed since transplant
+Prior allogeneic transplant
+Patients must have progressive, relapsed or refractory disease after:\r\n* At least one prior systemic anti-lymphoma regimen (chemotherapy or immunotherapy except for transformed mycosis fungoides as described previously)\r\n* Relapsed or failed autologous or allogeneic stem cell transplant
+Prior autologous, peripheral stem cell transplant within 12 weeks of the first dose of study drug.
+Autologous hematopoietic stem cell transplant or fludarabine chemotherapy within 6 months of study enrollment
+History of allogeneic stem cell transplant
+Has previously received an organ or progenitor/stem cell transplant.
+Back-up stem cell source
+Prior allogeneic stem cell transplant
+Prior autologous or allogeneic stem cell transplant (SCT)/bone marrow transplant within 12 months of signing the ICD. Subjects who received allogeneic SCT ? 12 months before signing the ICD may be eligible provided there is no ongoing graft-versus-host disease and no ongoing immune suppression therapy.
+Prior allogeneic stem cell transplant
+Transformed lymphoma is included if patients are ineligible for (or refuse) hematopoietic stem cell transplant
+At least 100 days after receiving any allogeneic hematopoietic stem cell transplant AND
+Patient has participated or is currently participating in any bone marrow derived autologous and allogeneic stem cell or gene therapy study.
+Received autologous stem cell transplant (ASCT) within 12 months
+Patients <100 days since prior allogeneic stem cell transplant
+Previous allogeneic hematopoietic stem cell transplant (HSCT transplant).
+frontline cytotoxic systemic therapy, for patients who are ineligible for stem cell transplant (SCT).
+Patients with previous allogeneic stem cell transplant.
+Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood within 24 months.
+Participants with a history of allogeneic stem cell transplant are eligible for study participation provided the following eligibility criteria are met:
+Prior bone marrow or stem cell transplant;
+INCLUSION FOR AUTOLOGOUS STEM CELL COLLECTION (PHASE 1 - TRANSPLANT RECIPIENT):
+INCLUSION CRITERIA TO PROCEED WITH AUTOLOGOUS STEM TRANSPLANT (PHASE 2 - TRANSPLANT RECIPIENT):
+Has not received a prior hematopoietic stem cell transplant within the previous 3 months
+Allogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within 90 days prior to to the first dose of study drug
+Patients are eligible 12 weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); patients must meet adequate bone marrow function definition post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria; patients status post-allogeneic stem cell transplant are excluded unless they are > 1 year post transplant, have been off all immunosuppressive therapy for more than 3 months and do not have active graft-versus-host disease (GVHD)
+Absolute lymphocyte count (ALC) ? 1,000/?l (? 500/?l after stem cell transplant) Note: After completion of dose escalation, patients with AML are not required to meet these hematologic criteria.
+ANC ? 1000/?l (? 500/?l after stem cell transplant)
+AML patients who are candidates for allogeneic stem cell transplant are excluded.
+Patient with a prior stem cell transplant (both autologous and allogeneic)
+Eligible for autologous stem cell transplant
+Recent salvage transplant (=< 6 months but >= 45 days post-transplant prior to study enrollment) for relapse
+Prior allogeneic transplant
+Prior allogeneic hematopoietic stem cell transplant
+Prior allogeneic hematopoietic stem cell transplant within </=4 months before first dose of study drug (Subjects must have completed immunosuppressive therapy before enrollment.
+Previous allogeneic stem cell transplant is allowed only if subjects are >100 days from stem cell transplant and do not have uncontrolled acute or chronic graft-vs-host disease
+Participant’s disease has relapsed after, is refractory to induction and/or salvage therapy, or has relapsed after hematopoietic stem cell transplant (HSCT)
+Patients must be within 30 – 120 days after hematopoietic stem cell transplant (HSCT)
+Previous autologous stem cell collection
+Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.
+Has received an allogeneic bone marrow or allogeneic stem cell transplant.
+Subject has had hematopoietic stem cell transplant (HSCT) and meets any of the following:
+Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study treatment.
+Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
+Prior allogeneic stem cell transplant, except for a specific cohort
+Patients who are candidates for hematopoietic stem cell transplant
+Patients who have received a prior autologous stem cell transplant are eligible if the transplant occurred > 6 months ago.
+Patients who have received a prior allogeneic stem cell transplant are eligible if:
+Prior organ or allogeneic stem cell transplant
+Subject has undergone an allogeneic stem cell transplant
+At least one prior therapy; patients with newly diagnosed tNHL are eligible at the time of transformation; prior autologous stem cell transplant is allowed
+Patients eligible for and willing to undergo autologous stem cell transplant with curative intent at the time of enrollment are not eligible
+Patients that received an autologous stem cell transplant must be at least 3 months post-transplant and recovered from acute transplant-related toxicities.
+Allogeneic stem cell transplant (SCT)
+Subjects must have received >= 2 prior regimens for relapsed disease; induction therapy and stem cell transplant will be considered as one regimen
+Receipt of an allogeneic transplant.
+Relapse after allogeneic stem cell transplantation prior to post-transplant day 30
+Prior treatment with hematopoietic stem cell transplant
+Treatment with prior autologous transplant is permitted
+Need for cytoreduction prior to allogeneic stem cell transplant.
+Patient with diffuse large B cell lymphoma has received or is ineligible for autologous or allogeneic stem cell transplant.
+No more than 4 prior lines of systemic anti-cancer therapy and no prior bone marrow transplant or stem cell transplant within 12 months of dosing, and no prior allogeneic transplant.
+Patients are not eligible post allogeneic stem cell transplant.
+The patient is not considered to be an immediate candidate for allogeneic stem cell transplant as determined by the investigator.
+Completion of autologous stem cell transplant (SCT) within 100 days prior to Cycle 1 Day 1
+History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of study drug.
+Autologous or allogeneic stem cell transplant within 3 months prior to enrolment [NOTE: subjects with evidence of active graph versus host disease are excluded].
+Prior allogeneic hematopoietic cell transplant
+History of allogeneic stem cell transplant
+Not currently a candidate for allogeneic hematopoietic stem cell transplant (HSCT).
+Prior allogeneic stem cell transplant patients will be allowed to enroll if they are past day +100 of transplant, have no active graft-versus-host-disease, are not on any immunosuppressants and have been off immunosuppressants for at least 4 weeks; prior autologous stem cell transplant patients will also be allowed to enter this study if they are past their day +100 of transplant
+Received an allogeneic stem cell transplant <3 months prior to the first dose of study medication, or presence of polymerase chain reaction (PCR)-detectable cytomegalovirus (CMV) in any post-allogeneic transplant participant
+Prior autologous hematopoietic stem cell infusion <4 weeks prior to first study dose
+Prior peripheral stem cell transplant within 12 weeks of the first dose of study treatment
+Prior autologous or allogeneic SCT
+Patient either is not a candidate for autologous stem cell transplant (ASCT), has declined the option of ASCT, or has relapsed after prior ASCT.
+Prior peripheral autologous stem cell transplant within 12 wks of Baseline.
+Prior allogeneic stem cell transplant.
+Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
+Subjects who are planning for or who are eligible for stem cell transplant
+Previous allogenic hematopoietic transplant within 90 d
+Previous allogeneic hematopoietic transplant within 90 days of study enrollment, Active GVHD requiring treatment.
+Previous allogeneic hematopoietic transplant within 90 days. Active GVHD requiring treatment
+Prior stem cell transplant
+Prior allogeneic stem cell transplant more than 6 months from the first transplant, in remission
+Prior autologous or allogeneic hematopoietic stem cell transplant
+Received any previous autologous stem cell transplant at least 12 weeks (3 months) prior.
+Previously received an allogeneic transplant.
+Prior peripheral stem-cell transplant within 12 weeks of the first dose of elotuzumab.
+Any prior allogeneic transplant.
+Prior autologous bone marrow or peripheral stem cell transplant less than 3 months prior to enrollment.
+Patients must have biopsy proven relapse of a solid tumor or leukemia (for diseases outlined); patients with solid tumors must have failed an autologous transplant or be considered ineligible to receive an autologous transplant because of organ dysfunction or inability to obtain a suitable autologous stem cell collection; in addition, patients will be eligible if their attending physician and transplant physician agree that autologous transplantation would not offer a significant chance of cure (i.e. > 20%); patients with solid tumors must be in complete remission or have minimal residual disease prior to transplant; patients with bulky disease (any single tumor mass measuring > 5 cm in greatest diameter) will not be eligible for this study; select patients with very high-risk solid tumors will be eligible in first complete or partial remission, as indicated below; all subjects with solid tumors who have not had stem cells collected for clinical purposes prior to enrolling on the study will undergo autologous stem cell harvest following standard clinical procedures before beginning the study conditioning regimen
+Subject may not have had hematopoietic stem cell transplant (HSCT) meeting any of the following: \r\n* Is within 2 months of transplant from cycle 1 day 1 (C1D1) \r\n* Has clinically significant graft-versus-host disease requiring treatment\r\n* Has >= grade 2 persistent non-hematological toxicity related to the transplant \r\n* Donor lymphocyte infusion (DLI) is not permitted < 30 days prior to study registration
+Patients who at the time of enrollment, are willing and eligible to receive a stem cell transplant will not be eligible to participate in this study
+For post autologous stem cell transplant (ASCT) patients, salvage therapy plus ASCT just prior to MDV9300 treatment must have resulted in a PR or stable disease;
+History of allogeneic stem cell transplant or transplant eligible
+Hematopoietic stem cell transplant recipient within 100 days post-transplant
+Patients who have undergone any prior transplant
+Prior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time without full hematopoietic recovery before Cycle 1 Day 1, or allogeneic stem cell transplant any time.
+Patient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entry
+Patients who have previously received an autologous SCT, are excluded if less than 90 days have elapsed from the time of transplant or the patient has not recovered from transplant-associated toxicities prior to the first scheduled dose of MEDI7247.
+Patients who have had an allogeneic stem cell transplant are excluded
+Has undergone a liver transplant, kidney transplant or nephrectomy.
+Has undergone a liver transplant, kidney transplant or nephrectomy.
+Any previous allogeneic hematopoietic stem cell transplant.
+Prior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time without full hematopoietic recovery before Cycle 1 Day 1 or allogeneic stem cell transplant any time.
+PRE-STEM CELL TRANSPLANT (SCT)
+Stem cell source: bone marrow, peripheral blood stem cell
+Prior allogenic stem cell or solid organ transplant
+Phase I: Currently scheduled for autologous or allogeneic transplant at the Hospital of the University of Pennsylvania
+Received >= 1 autologous or allogeneic (related or unrelated) HCT with curative intent at a participating transplant center for a hematologic malignancy
+Subjects must be undergoing autologous or allogeneic hematopoietic cell transplant (HSCT) with the BEAM conditioning regimen prior to HSCT
+Patients undergoing myeloablative allogenic hematopoietic stem cell transplant for any indication (both malignant and non-malignant) are eligible
+Prior therapies: Patients undergoing stem cell transplant of any kind
+Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration
+Allogeneic transplant recipients undergoing ablative transplants will also be eligible to participate; those receiving nonablative regimens (a small proportion of allogeneic transplant recipients at UWCCC) will be excluded
+Appropriate third party payer coverage for \Homebound Stem Cell Transplant Program\
+Planned stem cell transplant
+Scheduled to undergo an allogeneic hematopoietic stem cell transplant for any cancer or non-cancer illness
+POST-TRANSPLANT STATUS
+Patients must have a plan to receive a CD34-selected peripheral blood stem cell transplant with TBI-based conditioning
+Scheduled to undergo a hematopoietic stem cell transplant for any cancer or non-cancer illness from any autologous, related or unrelated donor source including bone marrow, peripheral blood progenitor cell, or umbilical cord blood
+Patients receiving myeloablative chemotherapy in preparation for allogeneic or autologous bone marrow or stem cell transplant
+Patient within 100 days of autologous/allogeneic (auto/allo) stem cell transplant and their stem cell physician does not approve yogurt ingestion
+TRANSPLANT PATIENTS: all patients undergoing planned allogeneic transplant (both malignant and non-malignant diagnoses)
+ONCOLOGY PATIENTS: patients with an oncology diagnosis that are or will be on a chemotherapy regimen that will last for an additional >= 3 months or are on or will be on a chemotherapy regimen for < 3 months and then proceed to transplant (allogeneic or autologous stem cell rescue) during the 3-month study period
+Patients who have undergone prior stem cell transplant will not be excluded from study entry as long as adequate marrow reserve is demonstrated (refer to hematologic parameters)
+Prior allogeneic hematopoietic stem cell transplant (HSCT)
+Planned allogeneic stem cell transplant with schedule that accommodates at least a 5 week exercise intervention, but not greater than 12 weeks
+Allogeneic hematopoietic cell transplant recipient
+Prior allogeneic hematopoietic stem cell transplantation; (patients may have received a prior autologous hematopoietic stem cell transplant)
+Allogenic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment
+Patients planned for upfront consolidation with high-dose therapy and autologous stem cell transplant
+Patients with DLBCL: Cancer progression after transplant, or be unwilling, unable or not an appropriate candidate for an autologous stem cell or bone marrow transplant
+NOTE: Prior autologous stem cell transplant as well as prior radiation to CNS does NOT prevent patients from enrollment into the trial
+Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion)
+Patient must not have had a previous allogeneic or syngeneic transplant; prior autologous transplant is allowed
+Participants must have acute GVHD as defined by the clinical impression of the treating physician; biopsy of the involved tissue, while encouraged, is not required for study entry; eligibility includes:\r\n* Acute GVHD developing after allogeneic hematopoietic stem cell transplantation using bone marrow, peripheral blood stem cells, or umbilical cord blood; recipients of non-myeloablative, reduced intensity and myeloablative transplants are eligible\r\n* Patients who develop acute GVHD after donor lymphocyte infusion (DLI) are eligible\r\n* There is no specified time window after day 0 of transplant as acute GVHD is only defined by clinical manifestations\r\n* Patients must have experienced neutrophil engraftment after hematopoietic cell transplant (HCT) as defined by absolute neutrophil counts >= 500/ul x 3 consecutive measurements
+Prior allogeneic hematopoietic cell transplant
+Enrollment in any other mucositis prevention study from screening up to day 45 post-stem cell transplant
+Patients with a prior stem cell transplant (SCT) must have failed the SCT
+Pediatric patients admitted to the hospital for a stem cell transplant
+Patients admitted to the transplant unit for autologous stem cell transplant, donor lymphocyte infusions, mesenchymal cell infusions, a second stem cell transplant, graft versus host disease or other complications post SCT will not be included
+English speaking parents of children ages 7 to 17 years who are admitted to the hospital for a stem cell transplant
+Parents of children admitted to the transplant unit for autologous stem cell transplant, donor lymphocyte infusions, mesenchymal cell infusions, a second stem cell transplant, graft versus host disease or other complications post SCT will not be included
+Scheduled to undergo either autologous or allogeneic hematopoietic stem cell transplant
+All transplant types will be eligible (autologous or allogeneic related or unrelated)
+Patients who have received their transplant at a different transplant center will not be eligible for the study
+Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells within 12 months
+Patients with previous hematopoietic stem cell transplant (HSCT)
+Prior autologous or allogeneic hematopoietic stem cell transplant
+Prior autologous or allogeneic HCT;
+Allogeneic HSCT recipients who are 3-35 months post-transplant
+Non-allogeneic (e.g. autologous) or syngeneic hematopoietic stem cell transplant (SCT) recipients
+Allogeneic HSCT recipients who are 3-23 months post-transplant
+Non-allogeneic (e.g. autologous) or syngeneic hematopoietic stem cell transplant (SCT) recipients
+Peripheral blood stem cells must have been used as the stem cell source
+Patients who have received an autologous transplant
+Must be candidates for peripheral blood stem cell transplants.
+Has previously received an allogenic hematopoietic stem cell transplant.
+Admission to the University of North Carolina (UNC) Hospital Bone Marrow Transplant Unit for allogeneic stem cell transplant
+Patients who have failed a prior autologous or allogeneic transplant are eligible; however, at least 6 months must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous or myeloablative allogeneic bone marrow transplant (BMT)
+Prior allogeneic transplant
+3-24 months post-transplant (any number of transplant)
+Children are not eligible as the transplant program is certified as an adult only transplant program
+One or more prior allogeneic stem cell transplantation (prior autologous transplant is acceptable)
+Diagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day 100 post-transplant
+Prior solid organ or stem cell transplant
+Prior allogeneic or autologous hematopoietic stem cell transplant in past 12 months
+Patients who have undergone a non-myeloablative stem cell transplant must have > 65% donor lymphoid hematopoiesis within 30 days of study enrollment
+ELIGIBILITY FOR CD34 SELECTED STEM CELL INFUSION FOLLOWING PRIOR ALLOGENEIC STEM CELL TRANSPLANT (MAY BE REFERRED TO AS A \BOOST\)
+Patient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplant
+Patients must have undergone an autologous transplant =< 12 months prior to transplant on this study or have received multi-agent or immunosuppressive chemotherapy within 3 months of the preparative regimen
+Underwent a previous related or unrelated allogeneic transplant
+Prior allogeneic stem cell transplant
+History of an allogeneic stem cell transplant. Subjects with a history of an autologous stem cell transplant are NOT excluded if they meet inclusion criteria related to history of autologous stem cell transplant.
+Prior autologous stem cell transplant (ASCT) ? 3 months before first dose.
+Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning.
+Autologous hematopoietic stem cell transplant < 3 months prior to enrollment.
+Prior allogeneic hematopoietic stem cell transplant.
+More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant)
+Prior allogenic stem cell or solid organ transplant
+Prior treatment with any adoptive T cell therapy; prior hematopoietic stem cell transplant (HSCT) is allowed
+Subject who is scheduled to have a cord blood transplant or a haploidentical transplant
+Prior allogeneic transplant
+Prior allogeneic transplant
+Has documented seropositivity for CMV within 1 year before hematopoietic stem cell transplant (HSCT)
+Receiving first allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord blood transplant)
+Planned haematopoietic stem cell transplant (HCT) during the study period. (If a HCT occurred prior to enrolment in the study, the subject may not receive study vaccine until at least 50 days after the transplant procedure).
+Prior allogeneic stem cell or solid organ transplant
+Suitable candidate for therapy with high-dose chemotherapy and autologous stem cell transplant (ASCT) as determined by the treating physician
+DONOR: Donors undergoing stem cell collection for match related allogeneic stem cell transplant
+Subjects planning to undergo allogeneic stem cell transplant within 6 months of enrollment
+Patients who have received a prior allogeneic transplant will be excluded
+Has previously had a hematopoetic stem cell transplant or solid organ transplant
+Prior autologous or allogeneic stem cell transplant within defined period of initiation of therapy
+Autologous stem cell transplant < 90 days prior to study day 1.
+Patients with a history of organ transplant including high dose chemotherapy with autologous stem cell rescue
+Subject has had prior allogeneic transplant.
+Recipient of a stem cell or bone marrow transplant.
+Has received an allogeneic transplant in the past; scheduled to receive a second allogeneic transplant
+Prior autologous stem cell transplant (ASCT) within 6 months preceding Cycle 1 Day 1.
+Prior allogeneic stem cell transplant and/or chimeric antigen receptor T-cell therapy at any time.
+Have received allogeneic stem cell transplant.
+Patients with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (e.g., transplant related side effects).
+Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ? 6 months prior to starting CC-90009.
+Stem cell transplant within the past 3 months
+Autologous or allogenic transplant within the 60 days prior to Screening.